ZA743934B - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
ZA743934B
ZA743934B ZA00743934A ZA743934A ZA743934B ZA 743934 B ZA743934 B ZA 743934B ZA 00743934 A ZA00743934 A ZA 00743934A ZA 743934 A ZA743934 A ZA 743934A ZA 743934 B ZA743934 B ZA 743934B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA00743934A
Other languages
English (en)
Inventor
M Cawthorne
J Green
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of ZA743934B publication Critical patent/ZA743934B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polyethers (AREA)
ZA00743934A 1973-07-05 1974-06-19 Pharmaceutical compositions ZA743934B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB32071/73A GB1479268A (en) 1973-07-05 1973-07-05 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA743934B true ZA743934B (en) 1975-06-25

Family

ID=10332744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00743934A ZA743934B (en) 1973-07-05 1974-06-19 Pharmaceutical compositions

Country Status (13)

Country Link
US (1) US4055635A (cg-RX-API-DMAC7.html)
JP (1) JPS5031019A (cg-RX-API-DMAC7.html)
AU (1) AU7067574A (cg-RX-API-DMAC7.html)
BE (1) BE817126A (cg-RX-API-DMAC7.html)
CA (1) CA1030871A (cg-RX-API-DMAC7.html)
DE (1) DE2432518A1 (cg-RX-API-DMAC7.html)
ES (1) ES428053A1 (cg-RX-API-DMAC7.html)
FR (1) FR2235699B1 (cg-RX-API-DMAC7.html)
GB (1) GB1479268A (cg-RX-API-DMAC7.html)
IE (1) IE40434B1 (cg-RX-API-DMAC7.html)
IL (1) IL45103A (cg-RX-API-DMAC7.html)
NL (1) NL7408985A (cg-RX-API-DMAC7.html)
ZA (1) ZA743934B (cg-RX-API-DMAC7.html)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2615844A1 (de) * 1976-04-10 1977-10-20 Knoll Ag Fibrinogen spaltendes enzymsystem
US4273873A (en) * 1977-10-25 1981-06-16 Unitika Ltd. Preparation of antithrombogenic polymeric materials
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
JPS54157816A (en) * 1978-05-27 1979-12-13 Unitika Ltd Fixing of bioactive substance to solid surface
IT1209419B (it) * 1980-07-01 1989-07-16 Texcontor Ets Composti ad attivita' mucolitica non assimilabili, processo per laloro preparazione e composizioni terapeutiche che li comprendono come principio attivo.
JPS58189122A (ja) * 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
SE8500341L (sv) * 1985-01-24 1986-07-25 Pharmacia Ab Desinfektionssats samt sett for desinfektion
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JP2896580B2 (ja) * 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
JP2975632B2 (ja) * 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
PT876165E (pt) * 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
AU729158B2 (en) 1997-01-31 2001-01-25 Genentech Inc. O-fucosyltransferase
US6552167B1 (en) 1998-08-28 2003-04-22 Gryphon Therapeutics, Inc. Polyamide chains of precise length
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
DE60331367D1 (de) * 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
BRPI0408358A (pt) 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7691603B2 (en) * 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1624847B1 (en) 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
NZ547168A (en) * 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
NZ550964A (en) 2004-04-28 2011-05-27 Angiodevice Internat Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
ES2339953T5 (es) * 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag Glicoformas de factor VII ligadas a O y método de fabricación
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP1789437A4 (en) * 2004-07-30 2008-11-05 Sinai School Medicine INHIBITORS OF NPC1L1 AND NPC1L1 AND METHODS OF USE THEREOF
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
EP1797192A1 (en) * 2004-09-29 2007-06-20 Novo Nordisk Health Care AG Modified proteins
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
JP2008538181A (ja) * 2005-03-30 2008-10-16 ネオス テクノロジーズ インコーポレイテッド 昆虫細胞系において増殖させたペプチドを生産するための製造方法
WO2006121569A2 (en) * 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
KR20100052501A (ko) 2007-08-27 2010-05-19 바이오제너릭스 에이지 Ｇ―ｃｓｆ 콘주게이트의 액상 포뮬레이션
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
KR101768792B1 (ko) 2008-01-22 2017-08-16 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
WO2017189988A1 (en) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908614A (en) * 1954-08-10 1959-10-13 Glaxo Lab Ltd Use of dextran in freeze-drying process
US3019171A (en) * 1957-11-25 1962-01-30 Ethicon Inc Activated enzyme compositions
SE337223B (cg-RX-API-DMAC7.html) * 1967-05-23 1971-08-02 Pharmacia Ab
NL6812443A (cg-RX-API-DMAC7.html) * 1968-08-31 1970-03-03
US3616229A (en) * 1968-09-27 1971-10-26 Monsanto Co Polymer-enzyme products comprising plurality of enzymes covalently bound to polymer
US3625827A (en) * 1968-09-27 1971-12-07 Monsanto Co Water-soluble polymer-enzyme products
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
BE758425A (fr) * 1969-12-02 1971-04-16 Baxter Laboratories Inc Streptokinase liee chimiquement a une matrice en carbohydrate (
US3876501A (en) * 1973-05-17 1975-04-08 Baxter Laboratories Inc Binding enzymes to activated water-soluble carbohydrates

Also Published As

Publication number Publication date
FR2235699B1 (cg-RX-API-DMAC7.html) 1978-07-21
AU7067574A (en) 1976-01-08
IE40434B1 (en) 1979-06-06
ES428053A1 (es) 1976-11-16
BE817126A (fr) 1975-01-02
FR2235699A1 (cg-RX-API-DMAC7.html) 1975-01-31
IL45103A (en) 1977-10-31
DE2432518A1 (de) 1975-01-30
IE40434L (en) 1975-01-05
GB1479268A (en) 1977-07-13
JPS5031019A (cg-RX-API-DMAC7.html) 1975-03-27
CA1030871A (en) 1978-05-09
IL45103A0 (en) 1974-10-22
NL7408985A (nl) 1975-01-07
US4055635A (en) 1977-10-25

Similar Documents

Publication Publication Date Title
ZA743934B (en) Pharmaceutical compositions
CA1026673A (en) Pharmaceutical compositions
AU6401073A (en) Compositions
HK72578A (en) Pharmaceutical compositions
ZA744373B (en) Pharmaceutical compositions
AU7362974A (en) Antichlorosis compositions
AU7201374A (en) Pharmaceutical compositions
ZA742956B (en) Pharmaceutical compositions containing triazolo-isoquinoline derivatives
ZA747675B (en) Hydrocurable compositions
ZA744488B (en) Pharmaceutical compositions
ZA745756B (en) Pharmaceutical compositions
ZA7461B (en) Pharmaceutical formulation
ZA747276B (en) Pharmaceutical compositions
ZA742064B (en) Pharmaceutical compositions
ZA746271B (en) Pharmaceutical compositions
PH11032A (en) Shampoo compositions
AU7349374A (en) Medicinal composition
KE2880A (en) Pharmaceutical compositions
IL46315A0 (en) Pharmaceutical compositions comprising vincamine
ZA741050B (en) Pharmaceutical compositions
IL46316A0 (en) Pharmaceutical compositions comprising vincamine
AU6539374A (en) Compositions
NZ175566A (en) Decapetides and pharmaceutical compositions
ZA733476B (en) Pharmaceutical compositions
IE38726L (en) Pharmaceutical compositions